Stratification of Barrett’s esophagus surveillance based on p53 immunohistochemistry: a cost-effectiveness analysis by an international collaborative group

Abstract

Background Surveillance of nondysplastic Barrett’s esophagus (NDBE) is recommended to identify progression to dysplasia; however, the most cost-effective strategy remains unclear. Mutation of TP53 or aberrant expression of p53 have been associated with the development of dysplasia in BE. We sought to determine if surveillance intervals for BE could be stratified based on p53 expression.

Methods A Markov model was developed for NDBE. Patients with NDBE underwent p53 immunohistochemistry (IHC) and those with abnormal p53 expression underwent surveillance endoscopy at 1 year, while patients with normal p53 expression underwent surveillance in 3 years. Patients with dysplasia underwent endoscopic therapy and surveillance.

Results On base-case analysis, the strategy of stratifying surveillance based on abnormal p53 IHC was cost-effective relative to conventional surveillance and a natural history model, with an incremental cost-effectiveness ratio (ICER) of $8258 for p53 IHC-based surveillance. Both the conventional and p53-stratified surveillance strategies dominated the natural history model. On probabilistic sensitivity analysis, the p53 IHC strategy ($28 652; 16.78 quality-adjusted life years [QALYs]) was more cost-effective than conventional surveillance ($25 679; 16.17 QALYs) with a net monetary benefit of $306 873 compared with conventional surveillance ($297 642), with an ICER <$50 000 in 96% of iterations. The p53-stratification strategy was associated with a 14% reduction in the overall endoscopy burden and a 59% increase in dysplasia detection.

Conclusion A surveillance strategy for BE based on abnormal p53 IHC is cost-effective relative to a conventional surveillance strategy and is likely to be associated with higher rates of dysplasia diagnosis.

Publikationsverlauf

Eingereicht: 14. Januar 2024

Angenommen nach Revision: 02. Mai 2024

Accepted Manuscript online:
02. Mai 2024

Artikel online veröffentlicht:
28. Juni 2024

• References

• 1 Shaheen NJ, Falk GW, Iyer PG. et al. ACG Clinical Guideline: diagnosis and management of Barrett's esophagus. Am J Gastroenterol 2016; 111: 30-50; quiz 51
• 2 Obermannova R, Alsina M, Cervantes A. et al. Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2022; 33: 992-1004 DOI: 10.1016/j.annonc.2022.07.003. (PMID: 35914638)
• 3 Dighe SG, Yan L, Mukherjee S. et al. Clinical and lifestyle-related prognostic indicators among esophageal adenocarcinoma patients receiving treatment at a comprehensive cancer center. Cancers (Basel) 2021; 13: 4653
• 4 Li S, Hoefnagel SJM, Krishnadath KK. Molecular biology and clinical management of esophageal adenocarcinoma. Cancers (Basel) 2023; 15: 5410 DOI: 10.3390/cancers15225410. (PMID: 38001670)
• 5 Shaheen NJ, Falk GW, Iyer PG. et al. Diagnosis and management of Barrett's esophagus: an updated ACG Guideline. Am J Gastroenterol 2022; 117: 559-587 DOI: 10.14309/ajg.0000000000001680. (PMID: 35354777)
• 6 Fitzgerald RC, di Pietro M, Ragunath K. et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut 2014; 63: 7-42 DOI: 10.1136/gutjnl-2013-305372. (PMID: 24165758)
• 7 Qumseya B, Sultan S. ASGE Standards Of Practice Committee. et al. ASGE guideline on screening and surveillance of Barrett's esophagus. Gastrointest Endosc 2019; 90: 335-359 e332
• 8 Whiteman DC, Appleyard M, Bahin FF. et al. Australian clinical practice guidelines for the diagnosis and management of Barrett's esophagus and early esophageal adenocarcinoma. J Gastroenterol Hepatol 2015; 30: 804-820 DOI: 10.1111/jgh.12913. (PMID: 25612140)
• 9 Codipilly DC, Chandar AK, Singh S. et al. The effect of endoscopic surveillance in patients with Barrett's esophagus: a systematic review and meta-analysis. Gastroenterology 2018; 154: 2068-2086 e2065
• 10 Sharma P, Falk GW, Weston AP. et al. Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus. Clin Gastroenterol Hepatol 2006; 4: 566-572
• 11 Sikkema M, Looman CW, Steyerberg EW. et al. Predictors for neoplastic progression in patients with Barrett's esophagus: a prospective cohort study. Am J Gastroenterol 2011; 106: 1231-1238
• 12 Buttar NS, Wang KK, Sebo TJ. et al. Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology 2001; 120: 1630-1639
• 13 Bennett C, Moayyedi P, Corley DA. et al. BOB CAT: a large-scale review and Delphi consensus for management of Barrett's esophagus with no dysplasia, indefinite for, or low-grade dysplasia. Am J Gastroenterol 2015; 110: 662-682; quiz 683 DOI: 10.1038/ajg.2015.322. (PMID: 26526079)
• 14 Singh S, Manickam P, Amin AV. et al. Incidence of esophageal adenocarcinoma in Barrett's esophagus with low-grade dysplasia: a systematic review and meta-analysis. Gastrointest Endosc 2014; 79: 897-909 e894 ; quiz 983 e891–e893
• 15 Wani S, Puli SR, Shaheen NJ. et al. Esophageal adenocarcinoma in Barrett's esophagus after endoscopic ablative therapy: a meta-analysis and systematic review. Am J Gastroenterol 2009; 104: 502-513 DOI: 10.1038/ajg.2008.31. (PMID: 19174812)
• 16 Sinh P, Anaparthy R, Young PE. et al. Clinical outcomes in patients with a diagnosis of "indefinite for dysplasia" in Barrett's esophagus: a multicenter cohort study. Endoscopy 2015; 47: 669-674
• 17 Kestens C, Leenders M, Offerhaus GJ. et al. Risk of neoplastic progression in Barrett's esophagus diagnosed as indefinite for dysplasia: a nationwide cohort study. Endoscopy 2015; 47: 409-414 DOI: 10.1055/s-0034-1391091. (PMID: 25521571)
• 18 Krishnamoorthi R, Mohan BP, Jayaraj M. et al. Risk of progression in Barrett's esophagus indefinite for dysplasia: a systematic review and meta-analysis. Gastrointest Endosc 2020; 91: 3-10 e13 DOI: 10.1016/j.gie.2019.07.037. (PMID: 31421077)
• 19 Shaheen NJ, Sharma P, Overholt BF. et al. Radiofrequency ablation in Barrett's esophagus with dysplasia. NEJM 2009; 360: 2277-2288
• 20 Peery AF, Shaheen NJ. Esophagus: endoscopic therapy for flat, dysplastic Barrett esophagus. Nat Rev Gastroenterol Hepatol 2011; 8: 186-187 DOI: 10.1038/nrgastro.2011.38. (PMID: 21386808)
• 21 Small AJ, Araujo JL, Leggett CL. et al. Radiofrequency ablation is associated with decreased neoplastic progression in patients with Barrett's esophagus and confirmed low-grade dysplasia. Gastroenterology 2015; 149: 567-576 e563 quiz e513–e564
• 22 Fudman DI, Lightdale CJ, Poneros JM. et al. Positive correlation between endoscopist radiofrequency ablation volume and response rates in Barrett's esophagus. Gastrointest Endosc 2014; 80: 71-77
• 23 Pouw RE, Klaver E, Phoa KN. et al. Radiofrequency ablation for low-grade dysplasia in Barrett's esophagus: long-term outcome of a randomized trial. Gastrointest Endosc 2020; 92: 569-574 DOI: 10.1016/j.gie.2020.03.3756. (PMID: 32217112)
• 24 Sami SS, Ravindran A, Kahn A. et al. Timeline and location of recurrence following successful ablation in Barrett's oesophagus: an international multicentre study. Gut 2019; 68: 1379-1385 DOI: 10.1136/gutjnl-2018-317513. (PMID: 30635408)
• 25 Haidry RJ, Butt MA, Dunn JM. et al. Improvement over time in outcomes for patients undergoing endoscopic therapy for Barrett's oesophagus-related neoplasia: 6-year experience from the first 500 patients treated in the UK patient registry. Gut 2015; 64: 1192-1199
• 26 Phoa KN, Pouw RE, Bisschops R. et al. Multimodality endoscopic eradication for neoplastic Barrett oesophagus: results of an European multicentre study (EURO-II). Gut 2016; 65: 555-562 DOI: 10.1136/gutjnl-2015-309298. (PMID: 25731874)
• 27 Haidry RJ, Lipman G, Banks MR. et al. Comparing outcome of radiofrequency ablation in Barrett's with high grade dysplasia and intramucosal carcinoma: a prospective multicenter UK registry. Endoscopy 2015; 47: 980-987
• 28 Hameeteman W, Tytgat GN, Houthoff HJ. et al. Barrett's esophagus: development of dysplasia and adenocarcinoma. Gastroenterology 1989; 96: 1249-1256 DOI: 10.1016/s0016-5085(89)80011-3. (PMID: 2703113)
• 29 Das A, Wells C, Kim HJ. et al. An economic analysis of endoscopic ablative therapy for management of nondysplastic Barrett's esophagus. Endoscopy 2009; 41: 400-408 DOI: 10.1055/s-0029-1214612. (PMID: 19418393)
• 30 Inadomi JM, Saxena N. Screening and surveillance for Barrett's esophagus: is it cost-effective?. Dig Dis Sci 2018; 63: 2094-2104 DOI: 10.1007/s10620-018-5148-7. (PMID: 29948571)
• 31 Giovannini M, Bories E, Pesenti C. et al. Circumferential endoscopic mucosal resection in Barrett's esophagus with high-grade intraepithelial neoplasia or mucosal cancer. Preliminary results in 21 patients. Endoscopy 2004; 36: 782-787 DOI: 10.1055/s-2004-825813. (PMID: 15326573)
• 32 Hirst NG, Gordon LG, Whiteman DC. et al. Is endoscopic surveillance for non-dysplastic Barrett's esophagus cost-effective? Review of economic evaluations. J Gastroenterol Hepatol 2011; 26: 247-254 DOI: 10.1111/j.1440-1746.2010.06506.x. (PMID: 21261712)
• 33 Kastelein F, van Olphen S, Steyerberg EW. et al. Surveillance in patients with long-segment Barrett's oesophagus: a cost-effectiveness analysis. Gut 2015; 64: 864-871
• 34 Omidvari AH, Ali A, Hazelton WD. et al. Optimizing management of patients with Barrett's esophagus and low-grade or no dysplasia based on comparative modeling. Clin Gastroenterol Hepatol 2020; 18: 1961-1969 DOI: 10.1016/j.cgh.2019.11.058. (PMID: 31816445)
• 35 Gordon LG, Mayne GC, Hirst NG. et al. Cost-effectiveness of endoscopic surveillance of non-dysplastic Barrett's esophagus. Gastrointest Endosc 2014; 79: 242-256 e246 DOI: 10.1016/j.gie.2013.07.046. (PMID: 24079411)
• 36 Galipeau PC, Li X, Blount PL. et al. NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. PLoS Med 2007; 4: e67 DOI: 10.1371/journal.pmed.0040067. (PMID: 17326708)
• 37 Stachler MD, Camarda ND, Deitrick C. et al. Detection of mutations in Barrett's esophagus before progression to high-grade dysplasia or adenocarcinoma. Gastroenterology 2018; 155: 156-167 (PMID: 30228724)
• 38 Koppert LB, Wijnhoven BP, van Dekken H. et al. The molecular biology of esophageal adenocarcinoma. J Surg Oncol 2005; 92: 169-190 DOI: 10.1002/jso.20359. (PMID: 16299787)
• 39 Polkowski W, van Lanschot JJ, Ten Kate FJ. et al. The value of p53 and Ki67 as markers for tumour progression in the Barrett's dysplasia-carcinoma sequence. Surg Oncol 1995; 4: 163-171 DOI: 10.1016/s0960-7404(10)80021-0. (PMID: 7582189)
• 40 Kastelein F, Biermann K, Steyerberg EW. et al. Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett's oesophagus. Gut 2013; 62: 1676-1683
• 41 Davelaar AL, Calpe S, Lau L. et al. Aberrant TP53 detected by combining immunohistochemistry and DNA-FISH improves Barrett's esophagus progression prediction: a prospective follow-up study. Genes Chromosomes Cancer 2015; 54: 82-90 DOI: 10.1002/gcc.22220. (PMID: 25284618)
• 42 Snyder P, Dunbar K, Cipher DJ. et al. Aberrant p53 immunostaining in Barrett's esophagus predicts neoplastic progression: systematic review and meta-analyses. Dig Dis Sci 2019; 64: 1089-1097 DOI: 10.1007/s10620-019-05586-7. (PMID: 30911864)
• 43 Redston M, Noffsinger A, Kim A. et al. Abnormal TP53 predicts risk of progression in patients with Barrett's esophagus regardless of a diagnosis of dysplasia. Gastroenterology 2022; 162: 468-481
• 44 Shaheen NJ, Falk GW, Iyer PG. et al. ACG Clinical Guideline: Diagnosis and management of Barrett’s esophagus. Am J Gastroenterol 2016; 111: 30-50 DOI: 10.1038/ajg.2015.322. (PMID: 26526079)
• 45 Pace M. European Commission, Eurostat. et al. Revision of the European Standard Population – Report of Eurostat's task force – 2013 edn. Zugriff am 20. Mai 2024 unter: https://data.europa.eu/doi10.2785/11470
• 46 Qumseya BJ, Wani S, Desai M. et al. Adverse events after radiofrequency ablation in patients with Barrett's esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2016; 14: 1086-1095 e1086
• 47 ASGE. Adverse events of upper GI endoscopy. Gastrointest Endosc 2012; 76: 707-718 DOI: 10.1016/j.gie.2012.03.252. (PMID: 22985638)
• 48 Menon S, Norman R, Mannath J. et al. Comparative cost-effectiveness of three post-radiofrequency ablation surveillance intervals for Barrett's esophagus. Endosc Int Open 2022; 10: E1053-E1064 DOI: 10.1055/a-1858-0945. (PMID: 35979029)
• 49 Tramontano AC, Chen Y, Watson TR. et al. Esophageal cancer treatment costs by phase of care and treatment modality, 2000–2013. Cancer Med 2019; 8: 5158-5172 DOI: 10.1002/cam4.2451. (PMID: 31347306)
• 50 McDougall JA, Furnback WE, Wang BCM. et al. Understanding the global measurement of willingness to pay in health. J Mark Access Health Policy 2020; 8: 1717030 DOI: 10.1080/20016689.2020.1717030. (PMID: 32158523)
• 51 Hur C, Choi SE, Rubenstein JH. et al. The cost effectiveness of radiofrequency ablation for Barrett's esophagus. Gastroenterology 2012; 143: 567-575 DOI: 10.1053/j.gastro.2012.05.010. (PMID: 22626608)
• 52 Pollit V, Graham D, Leonard C. et al. A cost-effectiveness analysis of endoscopic eradication therapy for management of dysplasia arising in patients with Barrett's oesophagus in the United Kingdom. Curr Med Res Opin 2019; 35: 805-815
• 53 Boger PC, Turner D, Roderick P. et al. A UK-based cost-utility analysis of radiofrequency ablation or oesophagectomy for the management of high-grade dysplasia in Barrett's oesophagus. Aliment Pharmacol Ther 2010; 32: 1332-1342 DOI: 10.1111/j.1365-2036.2010.04450.x. (PMID: 21050235)
• 54 Rastogi A, Puli S, El-Serag HB. et al. Incidence of esophageal adenocarcinoma in patients with Barrett's esophagus and high-grade dysplasia: a meta-analysis. Gastrointest Endosc 2008; 67: 394-398
• 55 Curvers WL, ten Kate FJ, Krishnadath KK. et al. Low-grade dysplasia in Barrett's esophagus: overdiagnosed and underestimated. Am J Gastroenterol 2010; 105: 1523-1530 DOI: 10.1038/ajg.2010.171. (PMID: 20461069)
• 56 Krishnamoorthi R, Borah B, Heien H. et al. Rates and predictors of progression to esophageal carcinoma in a large population-based Barrett's esophagus cohort. Gastrointest Endosc 2016; 84: 40-46 e47 DOI: 10.1016/j.gie.2015.12.036. (PMID: 26772891)
• 57 Fujii-Lau LL, Cinnor B, Shaheen N. et al. Recurrence of intestinal metaplasia and early neoplasia after endoscopic eradication therapy for Barrett's esophagus: a systematic review and meta-analysis. Endosc Int Open 2017; 5: E430-E449 DOI: 10.1055/s-0043-106578. (PMID: 28573176)
• 58 Cotton CC, Haidry R, Thrift AP. et al. Development of evidence-based surveillance intervals after radiofrequency ablation of Barrett's esophagus. Gastroenterology 2018; 155: 316-326 e316 DOI: 10.1053/j.gastro.2018.04.011. (PMID: 29655833)
• 59 Whitehead SJ, Ali S. Health outcomes in economic evaluation: the QALY and utilities. Br Med Bull 2010; 96: 5-21 DOI: 10.1093/bmb/ldq033. (PMID: 21037243)
• 60 Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practices. NEJM 1977; 31: 716-721 DOI: 10.1056/NEJM197703312961304. (PMID: 402576)
• 61 CMS. Centers for Medicare & Medicaid Services. In: Centers for Medicare & Medicaid Services; 2022 DOI: 10.3122/jabfm.2021.S1.200450 PubMed: 33622810.
• 62 Cantor SB. Cost-effectiveness analysis, extended dominance, and ethics: a quantitative assessment. Med Decis Making 1994; 14: 259-265 DOI: 10.1177/0272989X9401400308. (PMID: 7934713)
• 63 Provenzale D, Schmitt C, Wong JB. Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol 1999; 94: 2043-2053 DOI: 10.1111/j.1572-0241.1999.01276.x. (PMID: 10445526)
• 64 Inadomi JM, Somsouk M, Madanick RD. et al. A cost-utility analysis of ablative therapy for Barrett's esophagus. Gastroenterology 2009; 136: 2101-2114 e2101 DOI: 10.1053/j.gastro.2009.02.062. (PMID: 19272389)
• 65 Sonnenberg A, Soni A, Sampliner RE. Medical decision analysis of endoscopic surveillance of Barrett's oesophagus to prevent oesophageal adenocarcinoma. Aliment Pharmacol Ther 2002; 16: 41-50 DOI: 10.1046/j.1365-2036.2002.01146.x. (PMID: 11856077)
• 66 Garside R, Pitt M, Somerville M. et al. Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling. Health Technol Assess 2006; 10: 1-142 iii–iv
• 67 Sonnenberg A, Fennerty MB. Medical decision analysis of chemoprevention against esophageal adenocarcinoma. Gastroenterology 2003; 124: 1758-1766 DOI: 10.1016/s0016-5085(03)00393-7. (PMID: 12806608)
• 68 Gray NA, Odze RD, Spechler SJ. Buried metaplasia after endoscopic ablation of Barrett's esophagus: a systematic review. Am J Gastroenterol 2011; 106: 1899-1908 quiz 1909 DOI: 10.1038/ajg.2011.255. (PMID: 21826111)
• 69 Corley DA, Levin TR, Habel LA. et al. Surveillance and survival in Barrett's adenocarcinomas: a population-based study. Gastroenterology 2002; 122: 633-640 DOI: 10.1053/gast.2002.31879. (PMID: 11874995)
• 70 di Pietro M, Fitzgerald RC. BSG Barret’s Guidelines Working Group. Revised British Society of Gastroenterology recommendation on the diagnosis and management of Barrett's oesophagus with low-grade dysplasia. Gut 2018; 67: 392-393
• 71 Ganz RA, Overholt BF, Sharma VK. et al. Circumferential ablation of Barrett's esophagus that contains high-grade dysplasia: a U.S. Multicenter Registry. Gastrointest Endosc 2008; 68: 35-40
• 72 Critchley-Thorne RJ, Duits LC, Prichard JW. et al. A tissue systems pathology assay for high-risk Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 2016; 25: 958-968 DOI: 10.1158/1055-9965.EPI-15-1164. (PMID: 27197290)
• 73 Kaye PV. p53 Immunohistochemistry as a biomarker of dysplasia and neoplastic progression in Barrett's oesophagus. Diagn Histopathol 2015; 21: 89-98
• 74 Brankley SM, Halling KC, Jenkins SM. et al. Fluorescence in situ hybridization identifies high risk Barrett's patients likely to develop esophageal adenocarcinoma. Dis Esophagus 2016; 29: 513-519 DOI: 10.1111/dote.12372. (PMID: 26043762)
• 75 Dorer R, Odze RD. AMACR immunostaining is useful in detecting dysplastic epithelium in Barrett's esophagus, ulcerative colitis, and Crohn's disease. The American journal of surgical pathology 2006; 30: 871-877 DOI: 10.1097/01.pas.0000213268.30468.b4. (PMID: 16819330)
• 76 Sabo E, Beck AH, Montgomery EA. et al. Computerized morphometry as an aid in determining the grade of dysplasia and progression to adenocarcinoma in Barrett's esophagus. Lab Invest 2006; 86: 1261-1271 DOI: 10.1038/labinvest.3700481. (PMID: 17075582)
• 77 Hao J, Critchley-Thorne R, Diehl DL. et al. A cost-effectiveness analysis of an adenocarcinoma risk prediction multi-biomarker assay for patients with Barrett's esophagus. Clinicoecon Outcomes Res 2019; 11: 623-635
• 78 Iyer PG, Codipilly DC, Chandar AK. et al. Prediction of progression in Barrett's esophagus using a tissue systems pathology test: a pooled analysis of international multicenter studies. Clin Gastroenterol Hepatol 2022; 20: 2772-2779 e2778 DOI: 10.1016/j.cgh.2022.02.033. (PMID: 35217151)